One partner for comprehensive precision MRD in hematologic and solid tumors
Introducing the new MRD solution! AML NanoMRD™: Deeper MRD insights in just 3 days to accelerate hematologic clinical trials, even with limited sample input
With over a decade of supporting 300 + biopharma partners, NeoGenomics is a trusted leader in empowering biopharma partners in minimal/molecular residual disease to accelerate their clinical and translational programs across hematologic & solid tumors.
MRD solutions across tumor types and development stages
Detect disease before imaging to enable earlier intervention ahead of relapse
High-sensitivity quantification of low-level disease for treatment monitoring and relapse-risk assessment
Rapid cellular detection for hematologic malignancies
Flow cytometry enables direct quantification of residual malignant cells using immunophenotypic profiling. NeoGenomics delivers high-quality, flow cytometry–based MRD services built on standardized, tightly controlled staining and acquisition protocols. Results are analyzed by licensed clinical laboratory scientists and reviewed by board-certified hematopathologists for accuracy and consistency.
MRD endpoints in hematologic trials
Predicting relapse risk
Monitoring post-transplant recurrence
Measuring the depth of therapeutic response
New MRD solution
AML NanoMRD™
Transforming AML MRD: Minimal sample, maximum confidence, faster decisions.
An innovative, off-the-shelf, single-tube solution enabling precise and reliable relapse-risk assessment, deeper measurement of therapeutic response, and robust AML MRD tracking even with limited sample availability.
Earlier access to deeper clinical insights enables biopharma partners to make more informed development decisions, reduce program risk, and accelerate therapeutic development timelines.
Our tumor-informed MRD solution, RaDaR® ST, tracks patient-specific somatic mutations in circulating tumor DNA (ctDNA), enabling highly-sensitive detection of residual disease in solid tumors.
Early efficacy signals in solid tumors
Enrich trial populations
Molecular relapse detection months ahead of imaging
Support for MRD as a surrogate endpoint
*Sensitivity demonstrated across four independent analytical and clinical validation studies, with detection down to 1 ppm under study-specific conditions. LoD95 is 11 ppm. NeoGenomics Laboratories, Inc. Data on File.
Expertise You Can Trust. Resources You Can Act On.
